The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Chernichenko A.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Perfileva M.Yu.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Ryabov A.B.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Starinsky V.V.

P.A. Herzen Moscow Scientific Research Institute of Oncology

Mescheryakova I.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Plavnik R.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Gerasimov V.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Magomedova K.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Necessary and sufficient dose at stereotactic radiotherapy in functionally inoperable patients with non-small cell lung cancer

Authors:

Chernichenko A.V., Perfileva M.Yu., Ryabov A.B., Starinsky V.V., Mescheryakova I.A., Plavnik R.N., Gerasimov V.A., Magomedova K.M.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(6): 7‑12

Read: 410 times


To cite this article:

Chernichenko AV, Perfileva MYu, Ryabov AB, et al. Necessary and sufficient dose at stereotactic radiotherapy in functionally inoperable patients with non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;14(6):7‑12. (In Russ.)
https://doi.org/10.17116/onkolog2025140617

Recommended articles:
The place of stereotactic radiotherapy in the treatment of renal cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):86-90

References:

  1. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow: P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia; 2024. 276p. (In Russ.).
  2. Kaprin AD, Starinsky VV, Shakhzadova AO, eds. The state of cancer care for the population of Russia in 2023. Moscow: P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russia; 2024. 262p. (In Russ.).
  3. Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov YuM, Vladimirova LYu, et al. Malignant neoplasms of the bronchi and lung. Modern Oncology. 2022;24(3):269-304. (In Russ.). https://doi.org/10.26442/18151434.2022.3.201848
  4. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494-503.  https://doi.org/10.1016/s1470-2045(18)30896-9
  5. Rosen JE, Salazar MC, Wang Z, James BY, Decker RH, Kim AW, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2016;152(1):44-54.e9.  https://doi.org/10.1016/j.jtcvs.2016.03.060
  6. Spencer KL, Kennedy MPT, Lummis KL, Ellames DAB, Snee M, Brunelli A, et al. Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis. Eur Respir J. 2019;54:1801568. https://doi.org/10.1183/13993003.01568-2018
  7. Franks KN, McParland L, Webster J, Baldwin DR, Sebag-Montefiore D, Evison M, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Eur Respir J. 2020;56(5):2000118. https://doi.org/10.1183/13993003.00118-2020
  8. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623-31.  https://doi.org/10.1002/cncr.20539
  9. Guckenberger M. Dose and fractionation in stereotactic body radiation therapy for stage I non-small cell lung cancer: Lessons learned and where do we go next? Int J Radiat Oncol Biol Phys. 2015;93(4):765-8.  https://doi.org/10.1016/j.ijrobp.2015.08.025
  10. Yan M, Louie AV, Kotecha R, Ahmed MA, Zhang Z, Guckenberger M, et al. Stereotactic body radiotherapy for ultra-central lung tumors: a systematic review and meta-analysis and International Stereotactic Radiosurgery Society practice guidelines. Lung Cancer. 2023;182:107281. https://doi.org/10.1016/j.lungcan.2023.107281

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.